Eris is a pharmaceutical company that focuses on patient care, pioneering studies, and health & living solutions.

Eris

Eris Lifesciences Ltd is a publicly listed Indian pharmaceutical company and is a leading player in the domestic branded formulations market. Ranked #21 in the IPM, Eris has established a leading presence in its core cardio-metabolic franchise in just 16 years from inception. Eris is also successfully diversifying its business with 3 emerging therapies (Dermatology, Neuropsychiatry and Gynaecology) accounting for 26% of its revenue.

We began our journey 16 years ago in 2007 with the vision to make a meaningful impact in the management of chronic lifestyle related diseases. Today Chronic and Sub-chronic therapies account for ~ 87% of our revenue, and our product range spans ~ 90% of India’s Rs. 55,000+ crore chronic care market. Our business model is pivoted around specialist/ super specialist doctors and high end consulting physicians. We consistently endeavour to channel the advantages of cutting-edge medical knowledge to aid our clinicians and patients with better disease management options and outcomes

Chrys Capital

ERIS Lifesciences

Eris delivers 54% Q1 Revenue growth and 47% Q1 EBIDTA growth. Biocon business grows 14% in Q1 with significant margin expansion. Eris is now a Top-20 company in the IPM – gained 9 ranks since the IPO in 2017.

Eris delivers 37% Revenue growth and 30% PAT growth in Q4 FY24; Organic growth 15% in Branded Formulations.
#Q4Results #AnnualResults #Pharma #Powerofempathy #growth

Eris acquires Biocon Biologics’ India Branded Formulation business for INR 1242 cr. #eris #acquisition #powerofempathy #pharma

Eris Lifesciences expands its footprint in Sterile Injectables with the acquisition of 51% stake in Swiss Parenterals Ltd.
#eris #acquisition #powerofempathy #pharma

Eris delivers 15% Consolidated Revenue Growth with EBITDA margin of 36% in Q3 FY24; Branded formulations business clocks 37% EBITDA margin.
#q3fy24 #results #powerofempathy #growth

Eris announces H1 Revenue Growth of 13% and EBIDTA growth of 25%; Cash EPS grows 9.5%
#q2fy24 #results #eris #powerofempathy #growth

Eris acquires Biocon Divisions; Enters #Nephrology; Consolidates #Derma
#eris #powerofempathy #acquisition #pharma

Eris Lifesciences Limited manufactures, markets, and distributes pharmaceutical products in India. It offers various branded formulations in various therapeutic areas, such as cardiovascular, antidiabetes, anti-infective, antipyretics, vitamins/nutrients, gastroenterology, respiratory, gynecology, pediatrics, neurology, psychiatry, and pain/analgesics, as well as in-vitro fertilization, cosmetology, and dermatology. Eris Lifesciences Limited was incorporated in 2007 and is based in Ahmedabad, India.

Eris Lifesciences Limited

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Sep 4, 2024 1:34 AM	54d0d90c
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Sep 4, 2024 2:07 AM	667af408
company summary	general
signals	general
crunchbase trigger	general
crunchbase profile	general
li profile	general	Sep 4, 2024 1:34 AM	b93bd878
translate crunchbase fundingrounds	general
peers	general	Sep 4, 2024 1:34 AM	4407369d
news basic	general	Sep 4, 2024 1:34 AM	7013c194
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

IN:CO:ERIS

Eris

Last Close

1,374.20

25/11 09:40

Market Cap

141.09B

Beta: -

Volume Today

426.46K

Avg: -